IMMUNE THROMBOCYTOPENIC PURPURA
Clinical trials for IMMUNE THROMBOCYTOPENIC PURPURA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIC PURPURA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIC PURPURA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a denser dose of rituximab stop ITP relapses in kids?
Disease control Recruiting nowThis study tests whether giving rituximab more frequently (dose dense) can improve remission and reduce relapse in children and teens aged 1 to 21 with newly diagnosed, high-risk immune thrombocytopenic purpura (ITP). Participants must have a very low platelet count and at least …
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA
Phase: PHASE1 • Sponsor: New York Medical College • Aim: Disease control
Last updated May 26, 2026 07:14 UTC
-
New drug hopes to raise platelet counts in teens with chronic bleeding disorder
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 who have had immune thrombocytopenia (ITP) for over a year. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet levels. Par…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 26, 2026 07:09 UTC